<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03532763</url>
  </required_header>
  <id_info>
    <org_study_id>28701</org_study_id>
    <nct_id>NCT03532763</nct_id>
  </id_info>
  <brief_title>Anti-Inflammatory Effect of Tocotrienol Supplementation in Subjects With Moderately Elevated Inflammation</brief_title>
  <acronym>INTOC</acronym>
  <official_title>Anti-Inflammatory Effect of Tocotrienol Supplementation in Subjects With Moderately Elevated Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Malaysia Palm Oil Board</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Putra Malaysia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Malaysia Palm Oil Board</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to address the anti-inflammatory effect of tocotrienol
      supplementation in subjects with moderately elevated inflammation.

      It is hypothesized that 6 months supplementation of tocotrienols will reduce inflammatory
      markers of subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, randomized, placebo-controlled, parallel study comparing the effect of
      tocotrienols vs. placebo will be conducted in subjects with moderately elevated inflammation.
      Subjects will be supplemented with Tocovid Suprabio 200 mg twice daily or placebo for 6
      months. Fasting blood samples will be collected at baseline, 3 months, 6 months. A post-study
      fasting blood sample will be collected at 9 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double blind, placebo-controlled, parallel</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammation</measure>
    <time_frame>0, 3, 6, 9 months</time_frame>
    <description>Change in high-sensitivity c-reactive protein (hs-CRP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>0, 3, 6, 9 months</time_frame>
    <description>Changes in IL-6, IL-1alpha, IL-1beta, TNF-alpha, E-selectin, ICAM-1, VCAM-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombotic markers</measure>
    <time_frame>0, 3, 6, 9 months</time_frame>
    <description>Changes in PAI-1, D-dimer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>0, 3, 6, 9 months</time_frame>
    <description>Changes in TC, LDL, HDL, ApoA1, ApoB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose homeostasis</measure>
    <time_frame>0, 3, 6, 9 months</time_frame>
    <description>Changes in Glucose, insulin, c-peptide</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Inflammation</condition>
  <condition>Cardiovascular Risk Factor</condition>
  <arm_group>
    <arm_group_label>Tocotrienol-rich fraction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Tocotrienol-rich fraction</intervention_name>
    <description>1 capsule to be taken twice daily after meals for 6 months. Each capsule contains: 200 mg Tocotrienol-rich fraction</description>
    <arm_group_label>Tocotrienol-rich fraction</arm_group_label>
    <other_name>Tocovid Suprabio 200 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 capsule to be taken twice daily after meals for 6 months. Each capsule contains: Palm olein</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 30-60

          -  Elevated plasma hs-CRP level of &gt; 1 mg/L &lt; 10 mg/L

        Exclusion Criteria:

          -  Subjects with very high LDL-cholesterol ≥ 4.9 mmol/L

          -  Subjects with very high hs-CRP level ≥ 10 mg/L

          -  Pregnancy or lactation

          -  Current use of vitamin E or corticosteroids

          -  Significant hepatic and renal impairment

          -  Fever, cold or infection during bleeding day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>JU YEN FU, PhD</last_name>
    <phone>+60126392394</phone>
    <email>fujuyen@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>PUVANESWARI MEGANATHAN, Msc</last_name>
    <phone>+60123348356</phone>
    <email>mpuvaneswari@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Malaysian Palm Oil Board</name>
      <address>
        <city>Kajang</city>
        <state>Selangor</state>
        <zip>43000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JU YEN FU, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2018</study_first_submitted>
  <study_first_submitted_qc>May 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2018</study_first_posted>
  <last_update_submitted>May 20, 2018</last_update_submitted>
  <last_update_submitted_qc>May 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>Tocotrienols</keyword>
  <keyword>Cardiovascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

